Myles Wolf serves as Executive at Akebia Therapeutics, Inc., where they oversee executive responsibilities. Since joining the company, Myles Wolf has executed 4 insider transactions totaling $0, demonstrating a balanced approach to their equity position. Their most recent transaction on Jun 6, 2024 involved receiving (via award) 30,000 shares valued at $0.
Myles Wolf currently holds 97,681 shares of Akebia Therapeutics, Inc. (AKBA), valued at approximately $0. This represents their equity stake as Executive.
Based on SEC Form 4 filings, Myles Wolf has been a net neutral trader of AKBA stock. They have purchased $0 and sold $0 worth of shares.
Myles Wolf's most recent insider trade was on Jun 6, 2024, when they sold 30,000 shares at $0.00 per share.
Get notified when new Form 4 filings are submitted
| $N/A |
| Discretionary |
| Jun 8, 2022 | AKBA | $0 | Award | 13,700 | $N/A | Discretionary |
| Jun 2, 2021 | AKBA | $0 | Award | 13,700 | $N/A | Discretionary |